This is just one way high school students and college students in Israel make spending money.
Someone mentioned an article in Forbes about it not too long ago.
I've been in both a long time. More focused on ONCS now, but may move profits from ONCS into INO at some point. Both are great long-term.
The price to buy is anything less than 0.50. A year from now, that will look extremely good.
The only "red flag" that I see is one of Punit's obtuse comments: "We are on track to hit all milestones by the end of 2014. The only thing which could stop us is bad data."
What could be meant by "bad data?" Is it a mysterious 30th patient? (Or has that already been debunked?) Is it bad MCC data? What could it possibly be?
Here's to hoping that it's nothing!
JB--you are spot on with all of your observations. Definitely a "rigged" and unfair market to the retail investor. That's why so many have left and don't trust Wall Street, the SEC, the FDA, or any of the hedge funds. Most of those entities are crooks in bed with each other.
Kim needs to start throwing TDs or kicking field goals instead of punting each presentation.
I'm getting tired of his sports analogies until he starts to deliver on them.
I left the simpleton part for you.
I leave the more important questions to more relevant people.
What was our price pre-reverse split?
Unfortunately, there is a lot of sentiment with "big pharma" to produce "maintenance drugs" only, in order to provide recurring cash flow. In other words, keep people alive as long as possible, but don't cure them.
I know that sounds rather cruel and mean, but believe me that calculus does exist in the business of selling drugs; many are not selling a cure.